Investor Relations FAQ

You will need to contact our registrar and transfer agent - Computershare Investor Services Inc. at 1-866-332-8898, or (514) 982-8717 outside North America, for assistance.

If you are a registered shareholder, please contact our registrar and transfer agent - Computershare Investor Services Inc. at 1-866-332-8898,  or (514) 982-8717 outside North America.

If you are a registered shareholder, please contact our registrar and transfer agent - Computershare Investor Services Inc. at 1-866-332-8898, or (514) 982-8717 outside North America, to help you confirm the date of issue of your share certificate(s) if that corresponds to your original date(s) of purchase. If you are a non-registered shareholder, you should contact your broker, investment dealer, bank, trust company, trustee, nominee or other Intermediary for assistance.

Pursuant to the transaction agreement, Husky common shareholders received 0.7845 of a Cenovus common share and 0.0651 of a Cenovus common share purchase warrant in exchange for each Husky common share.

Each whole warrant entitles the holder to acquire one Cenovus common share until 4:30 pm (Calgary time) on January 1, 2026 at an exercise price of CAD$6.54 per share. It is five years from the date the transaction closed. The Cenovus warrants have been listed on the Toronto and New York exchanges under the ticker symbols (TSX: CVE WT) and (NYSE: CVE WS).

You can trade or exercise your warrants any time between now and January 1, 2026 through your brokerage.

Please visit the transaction proxy circular here for more information.

Former HSE common shareholders should consult their own tax advisors regarding the method for determining the ACB allocation that is appropriate for their particular circumstances for Canadian income tax purposes. The estimates of fair market value (FMV) information and the adjusted cost base (ACB) allocation of such FMV estimates between CVE Common Shares and CVE Warrants below are not binding on the Canada Revenue Agency, CVE/HSE or any shareholder. However, it is recommended that the FMV allocation between CVE Common Shares and CVE Warrants reported by former Husky common shareholders for Canadian income tax purposes be consistent with the allocation estimated by Cenovus. Effective as of January 1, 2021, each former HSE common shareholder received, in respect of each HSE Common share held, 0.7845 of a CVE Common Share and 0.0651 of a CVE Warrant. 788.5 million CVE Common Shares and 65.4 million CVE Warrants were issued to HSE common shareholders and CVE acquired 1,005 million issued and outstanding HSE Common Shares. Each whole CVE Warrant entitles the holder to acquire one CVE Common Share at any time up to January 1, 2026 at an exercise price of C$6.54. The following estimated FMV information may be useful for former HSE common shareholders in determining the allocation of a shareholder’s HSE Common Shares between Warrant Consideration Common Shares and Share Consideration Common Shares:

Cenovus has estimated the total FMV of the CVE Common Shares issued in exchange for a portion of the HSE Common Shares that Cenovus acquired under the Arrangement to be approximately C$6.1 billion, based on the closing price of C$7.75 per CVE Common Share on the TSX on December 31, 2020; and Cenovus has estimated the FMV of the CVE Warrants issued in exchange for a portion of the HSE Common Shares that Cenovus acquired under the Arrangement to be approximately C$216 million (or approximately $3.30 per CVE Warrant). Based on the foregoing estimated FMV information, the relative portion of a shareholder’s HSE Common Shares that are considered Warrant Consideration Common Shares is estimated to be 3.42% of the shareholder’s HSE Common Shares, and the relative portion of such HSE Common Shares that are considered to be Share Consideration Common Shares is estimated to be 96.58% of the shareholder’s HSE Common Shares. Former HSE common shareholders must determine their ACB based on their records. Cenovus (including Husky) does not have the information necessary to determine the ACB of the HSE Common Shares which have been exchanged, as the ACB will be unique to each former HSE common shareholder’s particular circumstances.

Former HSE shareholders who require assistance regarding the determination of the ACB of their HSE Common Shares should contact their tax advisor. For assistance obtaining records with respect to shareholdings, please contact your broker (if you are not a registered holder) or CVE/HSE’s transfer agent, Computershare - Telephone: toll-free North America: (866) 332-8898, outside North America: (514) 982-8717 (if you are a registered holder).

Cenovus common shares (ticker symbol: CVE) are listed on both the Toronto Stock Exchange and the New York Stock Exchange.

Cenovus cumulative redeemable preferred shares series 1, 2, 3, 5 and 7 are listed on the Toronto Stock Exchange under the symbols CVE.PR.A, CVE.PR.B, CVE.PR.C, CVE.PR.E and CVE.PR.G, respectively.

Cenovus common share purchase warrants are listed on both the Toronto Stock Exchange and the New York Stock Exchange under the symbols CVE.WT and CVE.WS, respectively.

Cenovus is headquartered in Calgary, Alberta. For additional details please visit the Contact us section of our website.

Cenovus was created through the division of Encana Corporation into two highly focused and independent publicly traded energy companies on December 1, 2009. For a full description of the transaction, please view the Information Circular (October 2009).

To purchase Cenovus common shares, preferred shares or warrants, you must do so through a brokerage service provider. Cenovus cannot provide investment advice or act as a financial advisor.

Yes, Cenovus has established a quarterly dividend payable to common shareholders. The declaration of dividends is at the sole discretion of the Board of Directors. For a list of dividends declared, please view the Dividend table.

Yes. Effective April 21, 2010, Cenovus established a Dividend Reinvestment Plan (DRIP) for its common shares. For further information, please view our DRIP, contact our transfer and DRIP agent, Computershare Investor Services Inc. at 1-866-332-8898 or visit the Cenovus Investor Centre.

If you are a registered shareholder, please contact our registrar and transfer and DRIP agent, Computershare Investor Services Inc. at 1-866-332-8898, or (514) 982-8717 outside North America, to assist you. If you are a beneficial shareholder, please contact your broker for assistance.

Yes, Canadian, U.S. and international shareholders are eligible to enrol in the DRIP. Once enroled, participation is automatic.

No. All purchases or sales of Cenovus securities must be done through a brokerage service provider.

For information regarding the common share history of Encana Corporation's (now Ovintiv Inc.) , historical financial reports and other shareholder materials, please visit their website at https://www.ovintiv.com/.

Shareholders received one Cenovus common share and one Encana common share for each Encana common share held. A share certificate was issued to you representing the Cenovus common shares.

For information regarding cost allocation and tax implications relating to the split, please visit Ovintiv's website at https://www.ovintiv.com/